Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05793034
Recruiting Not applicable

Predictive Factors for Survival in Aggressive Meningiomas

NCT05793034 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Not applicable
Started
2021-01-07
Last updated
2025-03-13

Condition(s) studied

MeningiomaMeningioma AtypicalAnaplastic Meningioma

Investigational drug(s) / intervention(s)

Biological biomarker assessment

Biological biomarker assessment: IHC, PCR, NGS, methylome

Study summary

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patient operated for atypical (grade 2) meningioma; or 2. Patient operated for anaplastic (grade 3) meningioma; 3. Timeframe for surgery, 1999-2019 Exclusion criteria 1\) Patient lost at follow-up

Primary outcome measure(s)

  • Recurrence-free survival (RFS) — 5 years on average
    Correlation from biomolecular data and RFS

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

The Management of Asymptomatic Carotid Stenosis Recruiting
Modular Neurological Examination for Early Risk Detection Active, not recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study Recruiting
Superior Cervical Ganglion in Parkinson's Disease Recruiting

Other trials for the same condition

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND Active, not recruiting
Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05793034 on ClinicalTrials.gov ↗ ← All trials in Italy